Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$62.45 -3.2%	$63.42	$43.70 ▼ $86.53	$1.99B	-1.49	43,575 shs	13,013 shs
CGON CG Oncology	$26.66 -0.2%	$26.13	$14.80 ▼ $40.47	$2.03B	0.87	964,171 shs	195,215 shs
IRON Disc Medicine	$59.41 -0.4%	$57.60	$30.82 ▼ $68.73	$2.07B	0.77	394,923 shs	104,160 shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+0.48%	-1.06%	+1.45%	-1.51%	+32.00%
CGON CG Oncology	+0.91%	+2.85%	+2.61%	+3.97%	-27.37%
IRON Disc Medicine	-0.48%	-0.15%	-0.23%	+27.59%	+20.57%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+15.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.9899 of 5 stars	3.5	4.0	3.3	0.8	0.6
CGON CG Oncology	1.4577 of 5 stars	3.5	0.0	3.2	0.8	0.0
IRON Disc Medicine	3.6724 of 5 stars	4.5	3.0	3.5	2.5	0.0
OPT Opthea	0.3998 of 5 stars	1.1	0.0	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	54.30% Upside
CGON CG Oncology	3.00	Buy	$54.30	104.52% Upside
IRON Disc Medicine	3.09	Buy	$98.30	65.55% Upside
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside

Current Analyst Ratings Breakdown

Latest OPT, IRON, CGON, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
8/18/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$85.00 ➝ $90.00
7/21/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/21/2025	IRON Disc Medicine	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00
7/16/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $53.00
7/10/2025	CGON CG Oncology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$40.00
7/3/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/17/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $56.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.71 per share	N/A
CGON CG Oncology	$551K	3,674.02	N/A	N/A	$8.79 per share	3.02
IRON Disc Medicine	N/A	N/A	N/A	N/A	$17.67 per share	N/A
OPT Opthea	$87.67K	5,986.77	N/A	N/A	($0.56) per share	-6.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$36.14M	-$1.55	N/A	N/A	N/A	N/A	-34.90%	-33.56%	11/11/2025 (Estimated)
CGON CG Oncology	-$88.04M	-$1.77	N/A	N/A	N/A	-15,945.17%	-19.37%	-18.72%	11/11/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$4.47	N/A	N/A	N/A	N/A	-26.60%	-24.58%	11/11/2025 (Estimated)
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)

Latest OPT, IRON, CGON, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	BLTE Belite Bio	-$0.47	-$0.50	-$0.03	-$0.50	N/A	N/A
8/8/2025	Q2 2025	CGON CG Oncology	-$0.49	-$0.54	-$0.05	-$0.54	$0.11 million	N/A
8/7/2025	Q2 2025	IRON Disc Medicine	-$1.17	-$1.58	-$0.41	-$1.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	23.15	23.15
CGON CG Oncology	N/A	22.15	22.15
IRON Disc Medicine	0.05	32.11	32.11
OPT Opthea	N/A	1.57	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CGON CG Oncology	26.56%
IRON Disc Medicine	83.70%
OPT Opthea	55.95%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CGON CG Oncology	7.40%
IRON Disc Medicine	3.64%
OPT Opthea	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
CGON CG Oncology	61	76.25 million	70.61 million	Optionable
IRON Disc Medicine	30	34.77 million	33.50 million	Not Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable

OPT, IRON, CGON, and BLTE Headlines

Recent News About These Companies

Opthea Limited Provides Corporate Update in Investor Presentation

August 20, 2025 | msn.com

Opthea parts with CEO, lays off over 80% of company

August 19, 2025 | ophthalmologytimes.comO

Opthea Provides Corporate Update

August 18, 2025 | globenewswire.com

Regal Partners Ltd Has $17.71 Million Position in Opthea Limited Unsponsored ADR (NASDAQ:OPT)

August 14, 2025 | marketbeat.com

Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected

July 2, 2025 | msn.com

Opthea Faces Leadership Changes Amidst Clinical Trial Setbacks

June 1, 2025 | tipranks.com

Biotech Dimerix lands $940m licensing deal for kidney drug sales

May 1, 2025 | afr.com

Phil King’s Regal successfully bets against Tesla, Nvidia

May 1, 2025 | afr.com

'No one is happy': Regal stockpickers face financial hit after Opthea blow up

April 21, 2025 | capitalbrief.comC

Regal’s King says his hedge funds will recover from March madness

April 16, 2025 | afr.com

Regal: Don’t catch the falling knife, wait for it to stick in the floor

April 16, 2025 | msn.com

Opthea to lay off approximately 65% of company

April 10, 2025 | ophthalmologytimes.comO

Opthea lays off 65% of staff after back-to-back phase 3 eye disease flops

April 10, 2025 | fiercebiotech.comF

BELL POTTER SECURITIES Downgrades Opthea (CKDXF)

April 9, 2025 | msn.com

BELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)

April 9, 2025 | msn.com

ASX drops as US jumbo China tariff takes effect

April 9, 2025 | afr.com

Opthea Limited (CKDXF) was downgraded to a Sell Rating at Bell Potter

April 3, 2025 | markets.businessinsider.com

Phil King’s Regal writes Opthea to zero and backs off risky bets

April 2, 2025 | afr.com

Opthea Ends Development of Sozinibercept in Wet AMD

March 31, 2025 | marketwatch.com

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

March 31, 2025 | endpts.comE

Opthea terminates COAST trial, announces ShORe trial misses endpoint

March 31, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OPT, IRON, CGON, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

$62.45 -2.06 (-3.19%)

As of 03:51 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

CG Oncology NASDAQ:CGON

$26.66 -0.06 (-0.22%)

As of 03:52 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Disc Medicine NASDAQ:IRON

$59.41 -0.25 (-0.42%)

As of 03:51 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Opthea NASDAQ:OPT

$3.41 0.00 (0.00%)

As of 08/28/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time